Kornimate/medical-research-clean huggingface dataset:
clinical investigation of an acrysof iq panoptix toric intraocular lens

Conditions: Aphakia; Corneal Astigmatism

Summary: the purpose of this study is to evaluate the effectiveness and safety of the tfnt20 low cylinder power intraocular lens when implanted in the eye to replace the natural lens following cataract removal.

subjects will attend a total of 5 to 9 visits, depending on whether one eye or both eyes are implanted. the second eye surgery, if applicable, will occur 1 to 30 days after the first eye surgery. total individual duration of participation will be up to 4 months, including an up to 2-month preoperative period. this study will be conducted in japan.

Eligibility criteria:
key inclusion criteria: * eligible to be implanted with acrysof iq panoptix toric intraocular lens model tfnt20 in at least one eye. * potential postoperative best corrected distance visual acuity (bcdva) of 0.5 decimal or better. * other protocol-specified inclusion criteria may apply. key exclusion criteria: * irregular corneal astigmatism. * history of anterior segment, posterior segment, or optic nerve pathology. * history of previous intraocular or corneal (refractive or trauma related) surgery. * any other planned ocular surgical procedures including but not limited to limbal relaxing incision (lri)/astigmatic keratotomy and laser assisted in situ keratomileusis (lasik). * other protocol-defined exclusion criteria may apply.

Keywords: cataract intraocular lens astigmatism toric
the longterm risk of advanced colorectal neoplasia after colonoscopy - a population-based cohort study in hong kong

Conditions: Colorectal Neoplasia; Colorectal Cancer

Summary: the primary objective of this study is to analyze the 15-year cumulative incidence of advanced colorectal neoplasia and crc-related mortality after the index colonoscopy.

this is a territory-wide retrospective observational cohort study using the clinical data analysis and reporting system (cdars). we will identify patients from cdars with colonoscopy performed from 1 january 2000 to 31 october 2020. other relevant diagnoses, procedures, concomitant drugs, laboratory parameters and pathology results will be retrieved and studied.

Eligibility criteria:
inclusion criteria: 1. all patients with colonoscopy performed in ha hospitals during the study period would be eligible for screening. exclusion criteria: 1. patients with documented personal history of colorectal cancers before the study period would be excluded.

Keywords: colonoscopy
evaluation of mdw for early detection of sepsis, clinical validity

Conditions: Severe Infection; Sepsis; Severe Sepsis

Summary: the purpose of this study is to confirm the clinical validity and the performance of the monocyte width distribution (mdw) parameter to detect the development of sepsis in a prospective study of emergency department (ed) adults who have blood draw including complete blood count with differential (cbc-diff) ordered upon presentation in a spanish \& french hospital and to verify cut-off for tri-potassium ethylenediaminetetraacetic acid (k3edta).

to confirm the clinical validity and performance of the monocyte width distribution (mdw) parameter to detect the development of sepsis in a prospective study of ed adults who have blood draw including cbc with differential ordered upon ed presentation. septic patients are identified as those with values equal to or above the mdw threshold and non-septic patients are those with mdw values below the threshold. as the anticoagulant used at the sites is k3edta, the cut-off value will be assessed using sepsis cases and all corresponding non-sepsis to confirm optimal cut-off. to explore the added value of this parameter in a patient diagnostic pathway that includes the use of procalcitonin (pct) or c reactive protein (crp) for the identification of septic patients all enrolled subjects will have pct/ crp assay performed per protocol plasma will be aliquot and stored frozen for subsequent testing at beckman coulter for other sepsis biomarker tests (additional pct\& crp tests and interleukin-6 (il-6) on the sponsor's devices

Eligibility criteria:
inclusion criteria: * cbc-diff upon presentation * adults (18-89) of all races \& ethnicities * signed informed consent exclusion criteria: * previously enrolled * incomplete informed consent * subject discharged \<4 hours from presentation * pct or crp not performed per protocol * pregnancy * prisoners * subjects under custody or guardianship

Keywords: mdw sepsis
exercise for fighting oncology repercussions after treatment

Conditions: Neoplasms

Summary: cancer survival rates are currently on the verge of 70% at 5 years since diagnosis. recent improvements in main cancer therapies including chemotherapy, radiotherapy, surgery and immunotherapy as well as developments of new biological therapies have significantly improved survival rates but unfortunately, cancer-related side effects continue to affect many patients even years after completion of main treatments. exercise has been shown to not only ameliorate cancer-related effects before, during and after treatment but also improve disease-free and overall survival rates by decreasing risk factors associated with cancer risk and improving resilience to treatment. in this non-randomised, three-arm study, we aim to assess the effects of three forms of exercise (i.e: nordic walking, aquatic exercise and functional exercise) on physical performance, cancer-related fatigue, health-related quality of life and cancer-specific symptoms in a wide range of cancer survivors.


Eligibility criteria:
inclusion criteria: * adults diagnosed with cancer * completion of any cancer therapy in the previous 3 months with the exception of hormonal therapy * patients living within the maresme area * no contraindications for exercise (oncology clearance or physical activity readiness questionnaire negative) exclusion criteria: * patients with any neurologic, cognitive or musculoskeletal impairments that prevent them to engage in any assessment test or exercise modality. * patients with unstable cardiac, respiratory or metabolic diseases * unable to speak or read catalan or spanish

Keywords: neoplasms exercise therapy side effects cancer-related fatigue quality of life
a biomarker exploration study of precision treatment in ovarian cancer

Conditions: Ovarian Cancer; Biomarker

Summary: this clinical trial aims to investigate the role of biomarkers in guiding precision treatment for ovarian cancer. the study will explore the effectiveness of personalized treatment strategies based on specific biomarkers identified in ovarian cancer patients. by analyzing the correlation between biomarker profiles and treatment outcomes, the trial seeks to optimize treatment decisions and improve overall survival rates in ovarian cancer patients.


Eligibility criteria:
inclusion criteria: * patients diagnosed with ovarian cancer. * willingness to undergo biomarker testing. * ability to provide informed consent for participation in the study. exclusion criteria: * inability to comply with study requirements or follow-up visits. * previous participation in a conflicting clinical trial.
multidisciplinary expert system for the assessment & management of complex brain disorders

Conditions: Dementia; Alzheimer Disease; Epilepsy; Sleep Disorder; Circadian Rhythm Disorders; Healthy

Summary: the multidisciplinary expert system for the assessment \& management of complex brain disorders (mes-cobrad) is an interdisciplinary project combining real-world data (rwd) from multiple clinical and consumer sources through comprehensive, cost-efficient, and fast protocols towards improving diagnostic accuracy and therapeutic outcomes in people with complex brain disorders (cobrad), as reflected in neurocognitive (dementia), sleep, and seizure (epilepsy) disorders and their interdependence. it brings together internationally recognized experts in medicine, engineering, computer science, social health science, law, and marketing and communication from across europe, and combines clinical information and scientific research in cobrad with technical innovation in secure data-sharing platforms, artificial intelligence algorithms, and expert systems of precision and personalized care, with a primary focus on improving the quality of life of patients, their caregivers, and the society at large. it leverages rwd from diverse cobrad populations across cultural, socioeconomic, educational, and health system backgrounds, with special attention on including vulnerable populations and minorities in an equitable manner and engaging key stakeholders to maximize project impact.


Eligibility criteria:
inclusion criteria: * all participants willing to undergo comprehensive assessment who visit one of three clinics (epilepsy, neurocognitive disorders, and sleep disorders), and healthy volunteers exclusion criteria: * participant disinterest

Keywords: artificial intelligence expert systems deep-phenotyping
telemedical algorithm-supported care for hypertension

Conditions: Arterial Hypertension; Cardiovascular Diseases

Summary: hypertension is a major global health issue, affecting around 9 million people in poland. while some studies indicate that telemonitoring benefits patients with hypertension, there is a lack of research evaluating tools that assist doctors in managing these patients. the objective of this study is to assess a blood pressure monitoring system with an integrated algorithm that aids doctors in the decision-making process.

the sot-art-ht study is a single-center, randomized, open-label trial aimed at comparing two strategies for managing arterial hypertension. patients in the control group will receive standard care, which includes regular visits to a hypertension clinic, while those in the intervention group will receive remote care through a specialized tele-informatic system designed to assist the physician. the trial will involve 200 participants, aged 18-80, with confirmed arterial hypertension and uncontrolled office blood pressure at the screening visit. both primary and secondary outcomes will be evaluated, with the study expected to be completed after 2026. however, early termination could occur if required by regulatory bodies, an ethics committee, or the scientific research committee.

Eligibility criteria:
inclusion criteria: 1. voluntarily signing an informed consent to participate in the study. 2. age between 18 and 80 years. 3. diagnosis of hypertension according to the polish society of hypertension criteria from 2019, either already treated or newly diagnosed. 4. blood pressure exceeding 140/90 mmhg in office measurements (during the screening visit). exclusion criteria: 1. suspicion or diagnosis of secondary hypertension. 2. pregnant women, breastfeeding women, or those planning pregnancy during the study period.
comparison of three scores for ultrasound assessment and monitoring of pulmonary aeration

Conditions: Atelectasis; Pneumonia; Acute Respiratory Distress Syndrome; Pulmonary Embolism; Hypoxemia; Dyspnea

Summary: this study is designed to compare three ultrasound-based aeration scores that were previously validated in specific populations, and to assess their correlation with computed tomographic measurement of pulmonary aeration in a population with different pathologies. hypothesis: the "loss of aeration score" will be more accurate than a simplified version and another widely used score, the "lung ultrasound score".

assessment of lung aeration may have a great impact in the management of mechanical ventilation and follow-up of diverse lung pathologies. computed tomographic scan is the gold standard method of lung aeration measurement but is rarely used because it requires transport of critically ill patients end exposes them to radiations. for these reasons, lung ultrasound would be an attractive alternative. variants of different ultrasound-based aeration scores have been validated in different specific populations, but there is no comparison study that defines the more accurate score that should be used in a population with different pathologies. methods: patients undergoing a computed tomographic scan for dyspnea or hypoxemia will have a standardized lung ultrasound examination on day 1. for mechanically ventilated patients only, a lung ultrasound examination will be repeated on day 2 to 4. end expiratory lung volume will also be measured in mechanically ventilated patients on day 1 and day 2 to 4. lung ultrasound images will be interpreted blindly. correlation of ultrasound-based aeration scores will be done with lung aeration measured by computed tomographic images.

Eligibility criteria:
inclusion criteria: * hospitalized or visiting the emergency room * will undergo a computed tomographic scan for dyspnea or hypoxemia exclusion criteria: * poor echogenicity (morbid obesity, multiple thoracic dressings) * contraindications to superior limbs or torso mobilization
ultrasound-guided axillary artery vs femoral artery cannulation.

Conditions: Critical Illness

Summary: the main purpose of the study is to compare two ultrasound-guided arterial cannulation procedures: in-plane infraclavicular axillary artery cannulation and out-of-plane femoral artery cannulation.


Eligibility criteria:
inclusion criteria: mechanically ventilated critically ill patients with indications for artery cannulation: * in whom radial artery cannulation is unable to perform or * in order to conduct hemodynamic monitoring using transpulmonary thermodilution exclusion criteria: * age less than 18 years * trauma and hematoma at the catheterization site * clinically significant coagulation disorders * infection at the catheterization site * lack of patients or closest relatives contents * precedent surgery operation into the femoral and axillary arteries * clinically significant ischemia of the limb at the cannulation side

Keywords: axillay artery cannulation femoral artery
gravid-child follow-up of the children´s health, growth and development within the gravid-study

Conditions: Vitamin D Deficiency; Body Composition; Vascular Health; Cardiometabolic Risk

Summary: gravid is a multi-ethnic population-based pregnancy cohort. pregnant women were invited to participate in the gravid study when registering for antenatal care in parts of the region of västra götaland in sweden in 2013-2014. all women registering for antenatal care were eligible for inclusion, as long as the pregnancy had not exceeded 16 gestational weeks. in total, 2125 pregnant women were recruited in gestational week 12 during two time-periods; fall 2013 and spring 2014. blood sampling was performed in gestational week \ 31 by midwifes. after delivery, the maternity records were obtained, to collect information on child's gender, birth weight and length and other possible birth outcomes.

in the gravid-child study, all healthy singleton children born within the gravid study will be invited to participate in a single clinical follow up. the follow-up will be conducted when all children are between 7-8 years of age. the study centre is located at the queen silvia children´s hospital in gothenburg, sweden. the follow up consist of several parts: 1. measurement of body weight and height, and waist circumference. 2. a questionnaire regarding health, physical activity, sleeping habits and diet. 3. endothelial function, a measure of how well the blood vessels dilute. 4. ultra sound of the thickness of the vessels on the neck, wrist and foot 5. pulse wave velocity, to measure the elasticity of the vessels on the neck and groin. 6. body composition using bioelectrical impedance. 7. blood pressure 8. a venous blood sample of maximum 18 ml will be drawn to analyze markers of cardiovascular health. blood lipids (total cholesterol, triglycerides, hdl cholesterol, ldl cholesterol), lipoprotein a, apolipoproteins (apo a1 and apo b), liver enzymes, glucose, insulin, hba1c, c-reactive protein, leptin, adiponectin, nutritional biomarkers (such as 25-hydroxyvitamin d) will be analyzed. the study hypothesis is that a low maternal vitamin d status increase the risk of an unfavorable child cardiometabolic risk profile, vascular health and body composition. recruitment start in january 2022 and will run for about a year.

Eligibility criteria:
inclusion criteria: * born within the gravid study * healthy * singleton exclusion criteria: * chromosomal abnormality * hyper-/hypothyroidism
safety study of passive immunization for patients with mild to moderate alzheimer's disease

Conditions: Alzheimer's Disease

Summary: this research study will assess whether aab-001 is safe, well tolerated and effective for use in patients with alzheimer's disease. aab-001 is a new drug that is not available outside this study. aab-001 is an antibody (a type of protein usually produced by white blood cells to destroy other substances in the body). in alzheimer's disease a protein called amyloid gathers in the brain and is thought to cause symptoms like memory loss and confusion. it is hoped that aab-001 will attach to the amyloid protein in your brain and help your body to remove it.


Eligibility criteria:
inclusion criteria: * diagnosis of probable ad * age from 50 to 85 years, inclusive * rosen modified hachinski ischemic score less than or equal to 4 * magnetic resonance imaging (mri) scan consistent with the diagnosis of ad * fluency in english * stable doses of medications exclusion criteria: * significant neurological disease other than ad * major psychiatric disorder * significant systemic illness * history of stroke or seizure * weight greater than 120kg (264 lbs.) * history of autoimmune disease * smoking more than 20 cigarettes per day * anticonvulsants, anti-parkinson's, anticoagulant, or narcotic medications * prior treatment with experimental immunotherapeutics or vaccines for ad * presence of pacemakers or foreign metal objects in the eyes, skin, or body

Keywords: alzheimer's caregivers alzheimer disease
follow up study on visual prognosis and complications of ectopia lentis lens

Conditions: Ectopia Lentis; Dislocation, Lens

Summary: this is a single-centre, observational cohort study with the following objectives: firstly, the investigators aim to evaluate the vision-related quality of life and mental health status in congenital ectopia lentis patients. secondly, the investigators target to investigate the correlations between genotype and clinical phenotype in patients of congenital ectopia lentis. thirdly, to explore the metabolic profiles in the aqueous humor (ah) of patients with congenital ectopia lentis. lastly, this study aims to explore the longitudinal changes of ocular biological parameters and complications in patients with postoperative congenital ectopia lens in the chinese population.

congenital ectopia lens is a rare ophthalmic disease that seriously harms the physical and mental health of patients. surgery is the only definite treatment at present. however, the changes in vision-related quality of life, mental health status, ocular biological parameters postoperative congenital dislocation of lens have not been systematically studied in the chinese population. in this trial, the investigators aim to evaluate the vision-related quality of life and mental health status in congenital ectopia lentis patients, investigate the correlations between genotype and clinical phenotype in patients of congenital ectopia lentis, explore the metabolic profiles in the aqueous humor (ah) of patients with congenital ectopia lentis, and explore the longitudinal changes of ocular biological parameters and complications in patients with postoperative congenital ectopia lens in the chinese population.

Eligibility criteria:
inclusion criteria: * diagnosed with congenital lens dislocation and age ≥ 3 years old. * agree to participate in this study with written informed consent from patients or legal guardians. exclusion criteria: * history of ophthalmic trauma or other ophthalmic surgeries. * combined with other ophthalmic diseases such as primary glaucoma, uveitis and corneal disease. * patients who could not cooperate in the examinations.
concurrent chemo-radiation form nsclc to a individualized mld

Conditions: Non-small Cell Lung Cancer

Summary: our group has shown in a modeling study that increasing the radiation dose to pre-specified normal tissue dose constrains could lead to increased tcp with the same ntcp in patients with non-concurrent chemo-radiation. in a subsequent phase i trial, in patients receiving non-concurrent chemo-radiation we showed the safety of this approach. here,we want to investigate its efficacy in a prospective study in patients with stage iii nsclc, who are selected for radical concurrent radiotherapy

eligible patients (see below) will receive radiotherapy to the primary tumor and the initially involved mediastinal lymph nodes to the following mld (mean lung dose): * mld=19 gy when fev1 and dlco\>50% of the predicted value * mld=15 gy when fev1 and/or dlco 40-49% of the predicted value * mld=10 gy when fev1 and/or dlco \<40% of the predicted value other dose-constrains: spinal cord max: 54 gy, brachial plexus (dmax):66 gy minimum tumor dose:54 gy. maximal tumor dose:69 gy radiotherapy will be delivered as follows: 1. first 3 weeks: 30 fractions: twice-daily fractions of 1.5 gy, with 8 to 10 h as interfraction-interval, 5 days per week total dose;45gy/30 fractions 2. thereafter: once-daily fractions of 2.0 gy, 5 days per week until the target dose has been reached. the radiation doses will be specified according to icru 50. lung density corrections will be applied, as well as all standard qa procedures. technical requirements are the same as in standard practice at maastro clinic. chemotherapy schedules allowed: 1. 1-2 cycles induction chemotherapy; any type will be registered. 2. concurrent part:(day1= first day of radiotherapy) 1. cisplatin - vinorelbine * cisplatin 50 mg/m2 day 2 and day 9 * vinorelbine 20 mg/m2 day 2 and day 9 * cisplatin 40mg/m2 day 23 * vinorelbine 15mg/m2 day 23 and day 30 2. cisplatin - docetaxel * cisplatin 50 mg/m2 day 2,9 and 29 * docetaxel 20 mg/m2 day 2, 9, 16, 23 and 29 3. cisplatin - etoposide * cisplatin 60 mg/m2 day 1 * docetaxel 120 mg/m2 day 1-3 q 3 weeks, 3 cycles when the calculated creatinin clearance is less than 60 ml/min, cisplatin may be substituted for carboplatin

Eligibility criteria:
inclusion criteria: * histological or cytological proven nsclc * uicc stage i-iii * performance status 0-2 * fev 1 and dlco at least 30% of the age-predicted value exclusion criteria: * not nsclc or mixed nsclc and other histologies (e.g. small cell carcinoma) * uicc stage iv * performance status 3 or more * fev 1 and dlco \< 30% of the age-predicted value

Keywords: radiotherapy nsclc stage iii non-small cell lung cancer